Intratumoral immunotherapy with aluminum hydroxide-activated IL-12 induces potent local and systemic immunity with minimal toxicity

Michael M Schmidt1, Gabriel Papadotis3, Sailaja Battula1, Howard Kaufman1, Darrell Irvine2, K. Dane Wittrup2

1Ankya Therapeutics, Boston, MA, USA; 2Massachusetts Institute of Technology, Cambridge, MA, USA

Intratumoral (IT) administration of IL-12-ABP complexes with Alhydrogel® particles results in potent immune activation at the injection site and retention of the cytokine/Alhydrogel® complex at the tumor site, giving rise to substantial local immune responses for over a week.

**ABSTRACT**

- **ANK-101** is a cytokine/Alhydrogel® fusion peptide that is phosphorylated at multiple sites.
- LANK-101 administration in murine models results in significant tumor regression and increased intratumoral CD8+ T cells.
- Combination with checkpoint blockade further enhances immune response.

**Conclusion**

ANK-101 is a promising therapeutic candidate for the treatment of solid tumors.

---

**Figure 1. Cytokines and other immune agonists are genetically fused to a proprietary alum-binding peptide (ABP) for local administration.**

**Figure 2. ANK-101 binds to the surface of tumor cells and activates immune cells.**

**Figure 3. ANK-101 administration significantly extends survival and increases the intratumoral CD8+/Treg ratio.**

**Figure 4. Enhanced monotherapy efficacy after 1 or 2 IT doses.**

**Figure 5. Activity against non-injected Lesions.**

---

**ANKYRA**